Brian Cheng
Stock Analyst at JP Morgan
(0)
# 4607
Out of 5,329 analysts
68
Total ratings
35.19%
Success rate
-18.34%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AAPG Ascentage Pharma Gro... | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Mar 27, 2025 | |
ITOS ITeos Therapeutics | Maintains: Overweight | 22 15 | 7.49 | 100.27% | 3 | Mar 6, 2025 | |
PTGX Protagonist Therapeu... | Maintains: Overweight | 53 57 | 45.16 | 26.22% | 5 | Mar 4, 2025 | |
NTLA Intellia Therapeutic... | Downgrades: Neutral | 45 13 | 8.66 | 50.12% | 4 | Feb 28, 2025 | |
BPMC Blueprint Medicines | Maintains: Overweight | 126 129 | 99.27 | 29.95% | 2 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 18 | 12.92 | 39.32% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 27 28 | 10.89 | 157.12% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 51 46 | 15.96 | 188.22% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 39 33 | 2.21 | 1393.21% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | 1.47 | 308.16% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | 8.88 | 170.27% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 | 0.4 | 1150% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 8 | 1.7 | 370.59% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 16 15 | 11.59 | 29.42% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 17 14 | 0.5 | 2700% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 6 | 0.63 | 852.38% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 24 | n/a | n/a | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 33 39 | n/a | n/a | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 7.85 | 154.78% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 71 85 | 12.54 | 577.83% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 21 | 8.72 | 140.83% | 1 | Aug 3, 2021 |